News & Media
Check out the latest news on MygoGenesis™ and its constellation of companies.
A Revolutionary Breakthrough in Biomedical Testing: AmeboGenesis Introduces Sustainable Amebocyte Production for LAL Testing to Detect Bacterial Contamination
Limulus Amebocyte Lysate (LAL) Can Now Be Produced Without Harvesting the Blood of ~800,000 Horseshoe Crabs Each Year, Which Will Help Restore Their Natural Population
GERMANTOWN, Md., March 26, 2024 (Newswire.com) – AmeboGenesis™ has achieved a significant milestone with the introduction of a sustainable Amebocyte production process. This innovative technology produces bio-identical Amebocytes necessary for the production of LAL for medical endotoxin testing without the need for harvesting horseshoe crab blood. The blood of horseshoe crabs, a source of Limulus Amebocyte Lysate (LAL), is a critical component in ensuring the safety of injectable drugs, vaccines, and implantable devices worldwide. The traditional method of obtaining LAL involves the harvesting and bleeding of ~800,000 horseshoe crabs annually, with a survival rate post-harvest that raises concerns for the horseshoe crabs’ survival as a potential endangered species. Read more.
Image Source via Business Insider.